2025-525113-22-00招募中1 期
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
Neurocrine Biosciences Inc.4 个研究点 分布在 2 个国家目标入组 15 人开始时间: 2026年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Neurocrine Medical Information Call Center
Scientific
Neurocrine Biosciences Inc.
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumorsadvanced refractory solid tumors2025-524192-24-00Samsung Bioepis Co. Ltd.40
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
撤回
2 期
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)2023-505334-10-00Marengo Therapeutics Inc.46
招募中
1 期
Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasmsMalignant B-cell neoplasms2025-524814-27-00Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre24